These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22275118)

  • 21. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
    Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
    Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst J; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Eur J Pharmacol; 2010 Apr; 632(1-3):93-102. PubMed ID: 20132813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NMR spectroscopic investigations of the activated p38α mitogen-activated protein kinase.
    Nielsen G; Schwalbe H
    Chembiochem; 2011 Nov; 12(17):2599-607. PubMed ID: 22012687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
    Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS
    J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.
    Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS
    J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
    Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
    Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
    J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
    J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the hydrogen bonding heteroatom-Lys53 interaction between the p38alpha mitogen-activated protein (MAP) kinase and pyridinyl-substituted 5-membered heterocyclic ring inhibitors.
    Abu Thaher B; Koch P; Schattel V; Laufer S
    J Med Chem; 2009 Apr; 52(8):2613-7. PubMed ID: 19301816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression.
    Aston NM; Bamborough P; Buckton JB; Edwards CD; Holmes DS; Jones KL; Patel VK; Smee PA; Somers DO; Vitulli G; Walker AL
    J Med Chem; 2009 Oct; 52(20):6257-69. PubMed ID: 19772287
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid identification of ligand-binding sites by using an assignment-free NMR approach.
    Kodama Y; Takeuchi K; Shimba N; Ishikawa K; Suzuki E; Shimada I; Takahashi H
    J Med Chem; 2013 Nov; 56(22):9342-50. PubMed ID: 24171460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Indolin-2-one p38α inhibitors I: design, profiling and crystallographic binding mode.
    Eastwood P; González J; Gómez E; Vidal B; Caturla F; Roca R; Balagué C; Orellana A; Domínguez M
    Bioorg Med Chem Lett; 2011 Jul; 21(14):4130-3. PubMed ID: 21696951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.
    Angell R; Aston NM; Bamborough P; Buckton JB; Cockerill S; deBoeck SJ; Edwards CD; Holmes DS; Jones KL; Laine DI; Patel S; Smee PA; Smith KJ; Somers DO; Walker AL
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4428-32. PubMed ID: 18614366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioisosteric Replacement of Arylamide-Linked Spine Residues with
    Pedreira JGB; Nahidino P; Kudolo M; Pantsar T; Berger BT; Forster M; Knapp S; Laufer S; Barreiro EJ
    J Med Chem; 2020 Jul; 63(13):7347-7354. PubMed ID: 32462866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based virtual screening approach to the discovery of p38 MAP kinase inhibitors.
    Choi H; Park HJ; Shin JC; Ko HS; Lee JK; Lee S; Park H; Hong S
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2195-9. PubMed ID: 22342625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Guaiane sesquiterpene lactones from Salvia nubicola (Lamiaceae).
    Ali MS; Ibrahim SA; Ahmed S; Lobkovsky E
    Chem Biodivers; 2007 Jan; 4(1):98-104. PubMed ID: 17256739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of a cycloheptenone derivative: an experimental and theoretical approach.
    de Oliveira KT; Júnior VL; Constantino MG; Donate PM; da Silva GV; Brocksom TJ; Frederico D
    Spectrochim Acta A Mol Biomol Spectrosc; 2006 Mar; 63(3):709-13. PubMed ID: 16024269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
    Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.